Abstract: Compositions, methods and kits for detecting viral nucleic acids. Targets that can be detected in accordance with the invention include HBV and/or HIV-1 and/or HCV nucleic acids. Particularly described are oligonucleotides that are useful as hybridization probes and amplification primers that facilitate detection of very low levels of HBV nucleic acids.
Type:
Grant
Filed:
July 6, 2010
Date of Patent:
August 18, 2015
Assignee:
Gen-Probe Incorporated
Inventors:
Jeffrey M. Linnen, Daniel P. Kolk, Janel M. Dockter, Damon K. Getman, Tadashi Yoshimura, Martha K. Ho-Sing-Loy, Reinhold B. Pollner, Leslie A. Stringfellow
Abstract: Single nucleotide polymorphic sites of the bovine MAP1B, PPP1R11, and DDX4 genes are associated with improved bull fertility as measured by e.g. sire conception rates. Nucleic acid molecules, arrays, kits, methods of genotyping and marker-assisted bovine breeding methods based on these SNPs are disclosed.
Abstract: An in depth analysis of prostate cancer prostatectomy samples which over-express the ERG oncogene led to the discovery of a novel gene translocation in prostate cancer, between the NDRG1 gene (N-myc downstream regulated gene 1) on chromosome 8 and the ERG oncogene on chromosome 21, leading to the expression of a chimeric NDRG1-ERG protein. Methods and compositions useful for diagnosing and treating prostate cancer characterized by NDRG1-ERG fusion are described.
Type:
Grant
Filed:
March 8, 2010
Date of Patent:
July 28, 2015
Assignee:
CORNELL UNIVERSITY
Inventors:
Mark A. Rubin, Dorothee Pflueger, David S. Rickman
Abstract: The invention relates to an in vitro method for predicting disease risks, progression of diseases, drug risks, success of treatment and for finding drug targets by looking for one or more genetic modifications in the promoter region of the CHK1 (CHEK1) gene on human chromosome 11q23, the genetic modifications being a substitution thymine for guanine in position ?1143 in the promoter of CHK1, of thymine for cytosine in position ?1400, a substitution of cytosine for thymine in position ?1453 or an insertion of one cytosine in position ?1454 and the genetic modifications being detected individually or in any combinations by way of known methods.
Abstract: A biocidal composition comprising 2,2-dibromomalonamide and a metal selected from silver, copper, and mixtures thereof, and its use for the control of microorganisms in aqueous and water-containing systems.
Type:
Grant
Filed:
August 3, 2011
Date of Patent:
June 23, 2015
Assignees:
Rohm and Haas Company, Dow Global Technologies LLC
Inventors:
Freddie L. Singleton, Tirthankar Ghosh, Kimberly S. Cagle
Abstract: Methods for detecting cancer that include hybridizing a set of chromosomal probes to a biological sample obtained from a patient, and identifying if aneusomic cells are present in a selected subset of cells obtained from the biological sample are described. A set of chromosomal probes and kits for detecting cancer that include sets of chromosomal probes, are also described.
Type:
Grant
Filed:
July 15, 2014
Date of Patent:
June 2, 2015
Assignees:
Mayo Foundation for Medical Education and Research, Abbott Molecular Inc.
Inventors:
Kevin C. Halling, Robert B. Jenkins, Walter King, Irina A. Sokolova, Steven A. Seelig
Abstract: Methods and compositions are described for detecting hydroxymethylated nucleotides (hmNs) in a polynucleotide preparation with a view to mapping the location of hmNs in a genome, quantifying the occurrence of hmNs at selected loci and correlating the occurrence of hmNs with gene expression and phenotypic traits. Embodiments describe the use of modifying enzymes together with site-specific endonucleases to detect the hmNs.
Type:
Grant
Filed:
August 25, 2010
Date of Patent:
May 19, 2015
Assignee:
New England Biolabs, Inc.
Inventors:
Jurate Bitinaite, Romualdas Vaisvila, Sriharsa Pradhan, Yu Zheng, Richard J. Roberts, Devora Cohen-Karni, Christopher Noren, Elisabeth A. Raleigh, Geoffrey Wilson, Hang-Gyeong Chin
Abstract: The present invention provides an assembly for the preparation of a medical device having a porous coating comprising hydrogen peroxide. Particularly interesting medical devices are catheters (such as urinary catheters), endoscopes, laryngoscopes, tubes for feeding, tubes for drainage, guide wires, condoms, urisheaths, barrier coatings e.g. for gloves, stents and other implants, extra corporeal blood conduits, membranes e.g. for dialysis, blood filters, devices for circulatory assistance, dressings for wound care, and ostomy bags. The coating is in particular a hydrophilic coating formed from cross-linked polyvinylpyrrolidone. In one embodiment, the assembly holds a dry catheter element in one compartment of a package and an aqueous hydrogen peroxide solution in another compartment. The solution may also comprise stabilizers, e.g. chelators, and osmolality increasing agents.
Type:
Grant
Filed:
February 26, 2004
Date of Patent:
May 12, 2015
Assignee:
Coloplast A/S
Inventors:
Bo Rud Nielsen, Soren Kristiansen, Bo Kjellman Bruun, Martin Sidenius
Abstract: A system and method for optimizing the systemic delivery of growth-arresting lipid-derived bioactive drugs or gene therapy agents to an animal or human in need of such agents utilizing nanoscale assembly systems, such as liposomes, resorbable and non-aggregating nanoparticle dispersions, metal or semiconductor nanoparticles, or polymeric materials such as dendrimers or hydrogels, each of which exhibit improved lipid solubility, cell permeability, an increased circulation half life and pharmacokinetic profile with improved tumor or vascular targeting.
Type:
Grant
Filed:
April 26, 2004
Date of Patent:
May 12, 2015
Assignee:
The Penn State Research Foundation
Inventors:
Mark Kester, Thomas Stover, Tao Lowe, James H. Adair, Young Shin Kim
Abstract: The present invention includes compositions and methods of making an activated polymeric nanoparticle for targeted drug delivery that includes a biocompatible polymer and an amphiphilic stabilizing agent non-covalently associated with a spacer compound that includes at least one electrophile that selectively reacts with any nucleophilic on a targeting agent and places the targeting agent on the exterior surface of a biodegradable nanoshell, wherein an active agent is loaded with the nanoshell.
Type:
Grant
Filed:
April 11, 2008
Date of Patent:
May 5, 2015
Assignee:
University of North Texas Health Science Center at Fort Worth
Inventors:
Arthur R. C. Braden, Jamboor K. Vishwanatha
Abstract: Modified-release multimicroparticulate pharmaceutical form capable of maintaining the modified release of the active principle in an alcoholic solution and of resisting attempts at misuse.
Abstract: Provided are methods for preventing and treating inflammation and organ injury after ischemia/reperfusion, and methods for treating lung injury, comprising administering a milk fat globule epidermal growth factor-factor VIII (MFG-E8) to a subject. Also provided are pharmaceutical compositions comprising MFG-E8 in dosage form for preventing and treating inflammation and organ injury after ischemia/reperfusion, and for treating lung injury, and methods of preparing a pharmaceutical composition for preventing and treating inflammation and organ injury after ischemia/reperfusion, and for treating lung injury, comprising formulating MFG-E8 in a pharmaceutical composition.
Type:
Grant
Filed:
November 13, 2008
Date of Patent:
April 28, 2015
Assignee:
The Feinstein Institute for Medical Research
Abstract: A method for predicting a subject's risk factors for ACE-related disorders includes detecting the allelic status of one or more polymorphisms in a nucleic acid sample of the subject.
Type:
Grant
Filed:
April 30, 2008
Date of Patent:
April 21, 2015
Assignee:
The Ohio State University Research Foundation
Inventors:
Wolfgang Sadee, Andrew D. Johnson, Danxin Wang, Audrey C. Papp
Abstract: The present invention pertains to a high drug load tablet comprising an active ingredient Compound I of formula or a pharmaceutically acceptable salt thereof in an amount from about 30% to 80% in weight of the active moiety based on the total weight of the tablet.
Type:
Grant
Filed:
January 23, 2014
Date of Patent:
April 21, 2015
Assignee:
Novartis AG
Inventors:
Christian-Peter Luftensteiner, Jean-Claude Bianchi, Joerg Ogorka, Oskar Kalb
Abstract: This invention provides for biocompatible and biodegradable syringeable liquid, implantable solid, and injectable gel pharmaceutical formulations useful for the treatment of systemic and local disease states.
Abstract: The present invention provides an implantable device having a biosoluble coating or a biosoluble body structure comprising a polyelectrolyte and a counterion and the methods of making and using the same.
Type:
Grant
Filed:
July 9, 2012
Date of Patent:
March 24, 2015
Assignee:
Abbott Cardiovascular Systems Inc.
Inventors:
Syed F. A. Hossainy, Mikael O. Trollsas, Lothar W. Kleiner
Abstract: It is an object of the present invention to provide a pest control composition capable of exerting a high effect on pests such as spider mites and aphids even at low concentration using a food/food additive with high safety to the human body and the environment. The present inventors have intensively studied to solve the above problem and found that, among polyglycerol fatty acid esters widely used as a food additive, a composition containing a polyglycerol fatty acid ester which has an HLB of 5 or less and is liquid at ordinary temperature and also a nonionic surfactant has a high effect on pests even at low concentration, and that the possibility for pests to develop resistance to the composition is extremely low, and the present invention has been completed.
Abstract: The present invention relates to a method for assessing a cancerous state of a mammal-derived specimen, which comprises: (1) a first step of measuring a methylation frequency of Neurofilament3 gene contained in a mammal-derived specimen or an index value having the correlation therewith, and (2) a second step of determining a cancerous state of the specimen based on a difference obtained by comparing the measured methylation frequency or the index value having the correlation therewith, with a control; and the like.
Type:
Grant
Filed:
September 15, 2004
Date of Patent:
March 17, 2015
Assignees:
Sumitomo Chemical Company, Limited, Japan as Represented by President of National Cancer Center
Abstract: A pharmaceutical composition comprising 3 wt. % to 50 wt. % telmisartan dispersed in a dissolving matrix comprising: (a) a basic agent in a molar ratio of basic agent:telmisartan of 1:1 to 10:|1|; (b) about 1 wt. % to about 20 wt. % of a surfactant or emulsifier; (c) 25 wt. % to 70 wt. % of a water-soluble |diluent|; and (d) 0 wt. % to 20 wt. % of one or more additional excipients and/or |adjuvants|; wherein the sum of all components is 100%, methods of making such pharmaceutical compositions, and their use.